Cost-utility analysis of first-line treatment with erlotinib versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer (NSCLC): economic analysis of EURTAC trial (O16.03)

Autor:	Vergnenegre, Alain, Rosell, Rafael, Massuti, Bartomeu, Pascal, Do, Corre, Romain, Felip, Enriqueta, Palmero, Ramon, Garcia Gomez, Ramon, Marinis, Filippo De, Santarpia, Mariacarmela, Wright, Elaine, Chouaid, Christos
Jazyk:	angličtina
Rok vydání:	2013
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______3978::efea54544be5b26cd17a8afe1e049ae6 http://hdl.handle.net/11570/3097541 Zobrazit plný text záznamu